vimarsana.com

Latest Breaking News On - L mind study - Page 1 : vimarsana.com

Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting

Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.

Translating recent evidenceReal world managementRefractory diffuse largeb cell lymphomaLargeb cell lymphomaMoving novel therapyDiffuse largeb cell lymphomaRelapsed refractory dlbclRr dlbclL mind studyL mind trialTl mindR chopFront mindFront mind studyFront mind trialZuma 7

Five-year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory DLBCL: Final Results From the Phase II L-MIND Study

Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Grzegorz nowakowskiFive year efficacyPatients with relapsedFinal results fromPartnership withDiffuse largeb cell lymphomaB cell lymphomaL mind trialL mind studyTl mindAnti cd19

vimarsana © 2020. All Rights Reserved.